Home / Oncology

Oncology

Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test

LAUSANNE, Switzerland–(BUSINESS WIRE)–Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology. The test will measure the response in patients with …

Read More »

New Technologies Offer the Possibility of Identifying Cancer from a Single Blood Draw

ALEXANDRIA, Va. – Two blood tests show promise as screening tools to identify patients with cancer of different types and across different stages. Results from the two approaches will be presented at the ASCO Breakthrough meeting October 11-13, 2019 in Bangkok. While the technology and science behind the two tests to be …

Read More »

Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research

PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement with the University of California Los Angeles (UCLA) to conduct preclinical studies evaluating the Company’s Lm technology in mouse tumor models of glioblastoma multiforme (GBM). Specifically, …

Read More »

GE Healthcare and Theragnostics Enter Global Commercial Partnership for Late Stage PSMA Diagnostic for Prostate Cancer

LONDON, Oct. 9, 2019 /PRNewswire/ — GE Healthcare and Theragnostics have entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. Theragnostics will lead the development of the tracer, GalliProst, while GE Healthcare will lead all pre-approval commercial preparations and as and when approval …

Read More »

FDA Grants Fast Track Designation to Mereo’s Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer

LONDON and REDWOOD CITY, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage biopharmaceutical company focused on rare diseases, today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation …

Read More »

Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments …

Read More »

Lilly’s Cyramza Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology

INDIANAPOLIS, Oct. 7, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that results from the global Phase 3 RELAY trial of CYRAMZA® (ramucirumab) in previously untreated patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) were published in The Lancet Oncology. In the RELAY study, treatment with CYRAMZA in combination with erlotinib demonstrated …

Read More »

Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of an expert panel consensus statement that includes appropriate use criteria for DecisionDx®-Melanoma in patients with cutaneous melanoma. The study was published in the peer-reviewed …

Read More »

Cepheid Receives FDA Clearance for Xpert BCR-ABL Ultra Test for Monitoring Disease Burden in CML Patients

SUNNYVALE, Calif., Oct. 2, 2019 /PRNewswire/ — Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden in patients with Chronic Myeloid Leukemia (CML). Xpert BCR-ABL Ultra, an in vitro diagnostic test, is the first FDA-cleared test …

Read More »

LineaRx’s iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Prostate Cancer Trial

STONY BROOK, N.Y.–(BUSINESS WIRE)–LineaRx, Inc., the majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) focused on next-generation biotherapeutics, announced today that its invasive Circulating Tumor Cells (iCTCs) platform demonstrated superior correlation over Prostate Specific Antigen (PSA) in an ongoing Phase II trial in recurrent prostate cancer. Most notably, the concentration of …

Read More »